A Phase I Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolism and Excretion of 14C-TA-8995 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2016
At a glance
- Drugs Obicetrapib (Primary)
- Indications Dyslipidaemias
- Focus Pharmacokinetics
- Sponsors Xention
- 26 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 14 Jul 2015 Planned End Date changed from 1 Jul 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.